Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1CNS 1

Conditions

Neoplasms 6Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Melanoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 15durvalumab 14Etoposide 14pembrolizumab 9atezolizumab 9Cisplatin 9Topotecan 8Nivolumab 7Specimen Handling 6olaparib 4berzosertib 4Temozolomide 4Magnetic Resonance Spectroscopy 4AMG 757 4tremelimumab 3Radiotherapy 3Radiosurgery 3PM 01183 3Ipilimumab 3Docetaxel 3Biopsy 3niraparib 2lenvatinib 2cabozantinib 2Platinum 2Irinotecan 2Fulvestrant 2veliparib 1tislelizumab 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Small Cell Lung Carcinoma × budigalimab × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡